U.S. must address IP and market access barriers abroad to protect American innovation

PhRMA recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2023 Special 301 Report. The comments highlight foreign government actions and policies that undermine...
Read More
Word of the Month: What is TRIPS?

What is TRIPS?
Read More
Expanding TRIPS waiver would jeopardize biopharmaceutical research and development

The United States has led the charge in the development of vaccines and treatments to combat COVID-19 thanks in large part to our robust innovation ecosystem, supported by intellectual property (IP)...
Read More
TRIPS waiver expansion risks public health

The Biden administration and other World Trade Organization members are considering expanding the harmful and unnecessary waiver of intellectual property (IP) protections under the Agreement on...
Read More
Expanding the WTO intellectual property waiver will hurt American jobs

The June decision by WTO members to waive commitments to protect intellectual property (IP) for COVID-19 vaccines under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement was...
Read More
PhRMA submission to USTR calls for urgent defense of American innovation abroad

The United States leads the world in medicine research, development and manufacturing, and international trade delivers those medicines to patients around the globe. But trade barriers imposed in...
Read More
Partnerships are driving global COVID-19 treatment access

Through the constant efforts of U.S. innovators and their global partners, COVID-19 treatments have continued to be distributed to patients around the world — changing the pandemic’s treatment...
Read More
The dangers of expanding the TRIPS waiver

World Trade Organization (WTO) members, including the United States, are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful...
Read More